Iter-4360dd15-0114-transcript
第 114 轮执行轨迹
→ call search_memory({"limit":8,"query":"4360dd15 BOLERO-2 investigator-assessed PFS randomized double-blind phase III accessible source"}) → call list_recent({"n":5})
→ call list_tools({})
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0113-transcript", "tags": "iteration transcript", "modified": "20260424215108000", "preview": "!! 第 113 轮执行轨迹
→ call search_memory({\\\"limit\\\":10,\\\"query\\\":\\\"4360dd15 383108"}, {"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹 →"}, {"title": "Iter-4360dd15-0055-transcript", "tags": "iteration transcript", "modified": "20260424195425000", "preview": "!! 第 55 轮执行轨迹 【tool:list_recent】
{"ok": true, "items": [{"title": "Iter-4360dd15-0113-reflection", "modified": "20260424215113000", "tags": "iteration reflection"}, {"title": "NEXT_FOCUS", "modified": "20260424215113000", "tags": "pinned focus"}, {"title": "先用可访问二源闭环再碰受限原文", "modified": "20260424215113000", "tags": "lesson evidence-chain trial-screening metadata-first"}, {"title": "Iter-4360dd15-0113-transcript", "modified": "20260424215108000", "tags": "iteration transcript"}, {"title": "BOLERO-2 PMID 22149876 的可访问非-NEJM 设计/终点复核", "modified": "20260424215102000", "tags": "fact knowledge 4360dd15 clinical-trials evidence-chain"}]}
【tool:list_tools】
{"ok": true, "tools": [{"name": "search_memory", "description": "在 TiddlyWiki 长期记忆中按关键字搜索（支持中文空格分隔），返回标题、标签、预览。每轮迭代开始前应先调用以回忆。", "custom": false}, {"name": "read_note", "description": "读取某一条 tiddler 的完整正文。", "custom": false}, {"name": "write_note", "description": "向 TiddlyWiki 写入（或覆盖）一条 tiddler。这是 Sisyphus 的长期记忆入口——每轮至少写一条。建议标签：knowledge, experiment, reflection, plan, idea, fact, question, lesson。TiddlyWiki 标记：!! 小标题，''粗体''，斜体，其它tiddler。", "custom": false}, {"name": "list_recent", "description": "列出最近修改过的 tiddler。", "custom": false}, {"name": "list_by_tag", "description": "按标签列出相关 tiddler。", "custom": false}, {"name": "run_python", "description": "在 workspace/ 下以子进程执行一段 Python 代码，返回 stdout/stderr。用于计算、模拟、验证假设、抓取公开数据（禁止任何破坏性操作）。", "custom": false}, {"name": "read_file", "description": "读取 workspace/ 下的某个文件。", "custom": false}, {"name": "write_file", "description": "向 workspace/ 下写入文件（默认覆盖，append=true 时追加）。", "custom": false}, {"name": "list_files", "description": "列出 workspace/ 下的文件。", "custom": false}, {"name": "web_fetch", "description": "抓取任意公开 URL（GET），返回剥离 HTML 后的纯文本。适合读论文摘要、文档、博客、百科。", "custom": false}, {"name": "web_search", "description": "用 DuckDuckGo 搜索互联网，返回 title/url/snippet 列表。找入口、找链接、调研时用。", "custom": false}, {"name": "wiki_search", "description": "维基百科搜索：返回若干条目的摘要和 URL。lang 默认 en，可传 zh 等。", "custom": false}, {"name": "arxiv_search", "description": "arXiv 论文检索：标题/作者/摘要/链接。理论、数学、物理、CS、bio 类前沿论文的主入口。", "custom": false}, {"name": "pubmed_search", "descriptio
→ call read_note({"title":"BOLERO-2 PMID 22149876 的可访问非-NEJM 设计/终点复核"})
→ call search_memory({"limit":10,"query":"4360dd15 BOLERO-2 investigator-assessed progression-free survival accessible source phase III double-blind randomized"})
→ call search_memory({"limit":10,"query":"4360dd15 BOLERO-2 ClinicalTrials.gov PFS investigator assessed"})
→ call search_memory({"limit":10,"query":"4360dd15 BOLERO-2 FDA approval review progression-free survival"})
【tool:read_note】
{"ok": true, "title": "BOLERO-2 PMID 22149876 的可访问非-NEJM 设计/终点复核", "tags": "fact knowledge 4360dd15 clinical-trials evidence-chain", "text": "!! BOLERO-2 PMID 22149876 的可访问非-NEJM 设计/终点复核\n\n''结论''\nPMID 22149876（BOLERO-2 原始主报告）可以用一个''非 NEJM''、可访问的权威来源直接复核其试验设计和主要终点：\n\n# 来自 eScholarship 的摘要页（可访问）\n- 试验设计：''phase 3, double-blind, randomized, international trial''\n- 比较方案：everolimus (10 mg/day) + exemestane (25 mg/day) vs placebo + exemestane\n- 主要终点：''PFS by local investigator review''，并且 ''confirmed by independent central radiology review''\n\n# 可核查入口\n- PMID 22149876\n- https://escholarship.org/uc/item/0715f3jd\n\n# 辅助一致性\n- ASCO 会议摘要检索结果也一致显示：''The primary end point was PFS by local investigator review.''\n- 这与 PMID 22149876/NEJM 主报告中的 primary endpoint 设定一致，且不依赖 NEJM 正文。\n\n''用途''\n以后锁定原始 trial metadata 时，可优先用：\n1. 检索题录/摘要；\n2. 第二独立可访问来源（如 eScholarship、PMC、ASCO 摘要页）做闭环；\n3. 再决定是否需要碰受限原文。"}
【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0113-transcript", "tags": "iteration transcript", "modified": "20260424215108000", "preview": "!! 第 113 轮执行轨迹
→ call search_memory({\"limit\":10,\"query\":\"4360dd15 BOLERO-2 PMID 22149876 primary endpoint trial design accessible authority\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0094-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424210844000\", \"preview\": \"!! 第 94 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 NEXT_FOCUS 剩余 10 条候选 PMID 研究类型 保留 排除 理由 extension follow-up secondary analysis\"}) → call list_recent({\"n\":10}) → call list_tools({}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0059-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424195947000\", \"preview\": \"!! 第 59 轮执行轨迹 → call search_memory({\"limit\":10,\"query\":\"4360dd15 NEXT_FOCUS PMID 10 条候选 研究类型 保留 排除 理由\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→"}, {"title": "Iter-4360dd15-0113-transcript", "tags": "iteration transcript", "modified": "20260424215108000", "preview": "!! 第 113 轮执行轨迹 → call search_memory({\\\"limit\\\":10,\\\"query\\\":\\\"4360dd15 383108"}, {"title": "Iter-4360dd15-0094-transcript", "tags": "iteration transcript", "modified": "20260424210844000", "preview": "!! 第 94 轮执行轨迹 【tool:search_memory】
{"ok": true, "results": [{"title": "Iter-4360dd15-0060-transcript", "tags": "iteration transcript", "modified": "20260424200117000", "preview": "!! 第 60 轮执行轨迹
→ call search_memory({\"limit\":10,\"query\":\"4360dd15 NEXT_FOCUS 剩余 10 条候选 PMID 研究类型 保留 排除 理由 extension follow-up secondary analysis\"}) → call list_recent({\"n\":10}) → call list_tools({}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0059-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424195947000\", \"preview\": \"!! 第 59 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 rapamycin review 2024 trial endpoint remaining 11\"}) → call list_recent({\"n\":8}) → call list_by_tag({\"limit\":20,\"tag\":\"4360dd15\"}) 【tool:search_memory】 {\"ok\": true, \"results\": [{\"title\": \"Iter-4360dd15-0007-transcript\", \"tags\": \"iteration transcript\", \"modified\": \"20260424174944000\", \"preview\": \"!! 第 7 轮执行轨迹 → call search_memory({\"limit\":8,\"query\":\"4360dd15 PMID 38310895 reference chain Crossref 75 references human trial rapamycin everolimus sirolimus\"}) → call list_recent({\"n\":8}) → call list_tools({}) 【tool:search → call web_fetch({"max_chars":7000,"url":"https://escholarship.org/uc/item/0715f3jd"})
→ call pubmed_search({"limit":5,"query":"22149876 BOLERO-2 investigator-assessed PFS double-blind randomized phase III"})
→ call web_search({"limit":5,"query":"BOLERO-2 eScholarship 0715f3jd investigator assessed PFS phase III randomized double blind"})
【tool:web_fetch】
{"ok": true, "url": "https://escholarship.org/uc/item/0715f3jd", "status": 202, "content_type": "text/html; charset=UTF-8", "text": "", "truncated": false}
【tool:pubmed_search】
{"ok": true, "query": "22149876 BOLERO-2 investigator-assessed PFS double-blind randomized phase III", "results": []}
【tool:web_search】
{"ok": true, "query": "BOLERO-2 eScholarship 0715f3jd investigator assessed PFS phase III randomized double blind", "results": [{"title": "Everolimus Plus Exemestane in Postmenopausal Patients ... - eScholarship", "url": "https://escholarship.org/uc/item/0715f3jd", "snippet": "Methods BOLERO-2 is a phase 3, double-blind , randomized , international trial comparing everolimus (10 mg/day) plus exemestane (25 mg/day) versus placebo plus exemestane in postmenopausal women with HR (+) advanced BC with recurrence/progression during or after NSAIs. The primary endpoint was PFS by local investigator review, and was confirmed by independent central radiology review. Overall ..."}, {"title": "PDF UC San Francisco Previously Published Works - eScholarship", "url": "https://escholarship.org/content/qt0715f3jd/qt0715f3jd.pdf", "snippet": "BOLERO-2 is a phase 3, double-blind , randomized , international trial comparing everolimus (10 mg/day) plus exemestane (25 mg/day) versus placebo plus exemestane in postmenopausal women with HR?advanced BC with recurrence/progression during or after S. Noguchi Department of Breast and Endocrine Surgery, Osaka University, Suita, Osaka 565-0871, Japan"}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://www.annalsofoncology.org/article/S0923-7534(19)36905-4/fulltext", "snippet": "BOLERO-2 is a phase III , double-blind , randomized international trial comparing EVE 10 mg/day plus EXE 25 mg/day versus placebo (
→ call web_fetch({"max_chars":8000,"url":"https://clinicaltrials.gov/study/NCT00863655"})
→ call web_fetch({"max_chars":8000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/"})
【tool:web_fetch】
{"ok": false, "error": "Client error '403 Forbidden' for url 'https://clinicaltrials.gov/study/NCT00863655'\nFor more information check: https://developer.mozilla.org/en-US/docs/Web/HTTP/Status/403"}
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Ann Oncol . 2014 Sep 17;25(12):2357–2362. doi: 10.1093/annonc/mdu456 Search in PMC Search in PubMed View in NLM Catalog Add to search Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast canc
→ call pubmed_search({"limit":10,"query":"\"Everolimus plus exemestane\" BOLERO-2 PMID 22149876"})
→ call web_search({"limit":8,"query":"PMID 22149876 BOLERO-2 PubMed everolimus exemestane title"})
→ call web_fetch({"max_chars":7000,"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/"})
【tool:pubmed_search】
{"ok": true, "query": "\"Everolimus plus exemestane\" BOLERO-2 PMID 22149876", "results": []}
【tool:web_search】
{"ok": true, "query": "PMID 22149876 BOLERO-2 PubMed everolimus exemestane title", "results": [{"title": "The BOLERO-2 trial: the addition of everolimus to exemestane ... - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/22764762/", "snippet": "Research has indicated that aberrant signaling through the mTOR pathway is associated with resistance to endocrine therapies. The BOLERO-2 trial examined the effects on progression-free survival of the addition of everolimus to exemestane in a patient population of postmenopausal, hormone receptor-positive, advanced breast cancer."}, {"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "In this phase 3, randomized trial, we compared everolimus and exemestane versus exemestane and placebo (randomly assigned in a 2:1 ratio) in 724 patients with hormone-receptor-positive advanced ..."}, {"title": "Everolimus in postmenopausal hormone-receptor-positive advanced breast ...", "url": "https://europepmc.org/article/MED/22149876", "snippet": "In this phase 3, randomized trial, we compared everolimus and exemestane versus exemestane and placebo (randomly assigned in a 2:1 ratio) in 724 patients with hormone-receptor-positive advanced breast cancer who had recurrence or progression while receiving previous therapy with a nonsteroidal aromatase inhibitor in the adjuvant setting or to ..."}, {"title": "Everolimus in Combination With Exemesta
【tool:web_fetch】
{"ok": true, "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/", "status": 200, "content_type": "text/html; charset=utf-8", "text": "Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2 - PMC Skip to main content An official website of the United States government Here's how you know Here's how you know Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ( Lock Locked padlock icon ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites. Search Log in Dashboard Publications Account settings Log out Search… Search NCBI Primary site navigation Search Logged in as: Dashboard Publications Account settings Log in Search PMC Full-Text Archive Search in PMC Journal List User Guide PERMALINK Copy As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with, the contents by NLM or the National Institutes of Health. Learn more: PMC Disclaimer | PMC Copyright Notice Ann Oncol . 2014 Sep 17;25(12):2357–2362. doi: 10.1093/annonc/mdu456 Search in PMC Search in PubMed View in NLM Catalog Add to search Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast canc
→ call web_search({"limit":10,"query":"PMID 22149876 Europe PMC BOLERO-2 abstract investigator review PFS"})
→ call web_search({"limit":10,"query":"\"22149876\" BOLERO-2 EuropePMC abstract"})
→ call web_search({"limit":10,"query":"BOLERO-2 investigator-assessed PFS local investigator review abstract"})
【tool:web_search】
{"ok": true, "query": "PMID 22149876 Europe PMC BOLERO-2 abstract investigator review PFS", "results": [{"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "In this phase 3, randomized trial, we compared everolimus and exemestane versus exemestane and placebo (randomly assigned in a 2:1 ratio) in 724 patients with hormone-receptor-positive advanced ..."}, {"title": "Checking your browser - reCAPTCHA - PubMed", "url": "https://pubmed.ncbi.nlm.nih.gov/22149876/", "snippet": "Everolimus combined with an aromatase inhibitor improved progression-free survival in patients with hormone-receptor-positive advanced breast cancer previously treated with nonsteroidal aromatase inhibitors. (Funded by Novartis; BOLERO-2 ClinicalTrials.gov number, NCT00863655.)."}, {"title": "The BOLERO-2 trial: the addition of everolimus to ... - Europe PMC", "url": "https://europepmc.org/articles/PMC3466807", "snippet": "The BOLERO-2 trial examined the effects on progression-free survival of the addition of everolimus to exemestane in a patient population of postmenopausal, hormone receptor-positive, advanced breast cancer."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://www.annalsofoncology.org/article/S0923-7534(19)36905-4/fulltext", "snippet": "The BOLERO-2 study previously demonstrated that adding everolimus (EVE) to exemestane (EXE) significa
【tool:web_search】
{"ok": true, "query": "\"22149876\" BOLERO-2 EuropePMC abstract", "results": []}
【tool:web_search】
{"ok": true, "query": "BOLERO-2 investigator-assessed PFS local investigator review abstract", "results": [{"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://www.annalsofoncology.org/article/S0923-7534(19)36905-4/fulltext", "snippet": "BOLERO-2 is a phase III, double-blind, randomized international trial comparing EVE 10 mg/day plus EXE 25 mg/day versus placebo (PBO) + EXE 25 mg/day in postmenopausal women with HR + advanced breast cancer with prior exposure to NSAIs. The primary end point was PFS by local investigator assessment; OS was a key secondary end point."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/", "snippet": "The primary end point was PFS as assessed by local investigator (per RECIST 1.0) [9]; OS was a key secondary end point. Safety assessments are described in the supplementary materials, available at Annals of Oncology online. Poststudy anticancer therapies were recorded for at least the first treatment after discontinuation."}, {"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "The primary end point was progression-free survival, on the basis of radiographic studies assessed by the local investigators , with central assessment by an independent radiology committee used in ..."}, {"title": "Everolimus in Postme
→ call web_fetch({"max_chars":7000,"url":"https://europepmc.org/article/MED/22149876"})
→ call web_search({"limit":10,"query":"Europe PMC 22149876 BOLERO-2 abstract primary endpoint investigator review"})
→ call web_search({"limit":10,"query":"\"PMID 22149876\" \"primary end point was PFS by local investigator review\""})
【tool:web_fetch】
{"ok": true, "url": "https://europepmc.org/article/MED/22149876", "status": 200, "content_type": "text/html;charset=UTF-8", "text": "Europe PMC Europe PMC 1 Sign in | Create an account https://orcid.org https://plus.europepmc.org Europe PMC Menu About About Europe PMC Preprints in Europe PMC Funders Become a funder Governance Roadmap Outreach Tools Tools overview Article status monitor Grant finder External links service RSS feeds About SciLite annotations Annotations submission service Developers Developer resources Articles RESTful API Grants RESTful API API case studies SOAP web service Annotations API OAI service Bulk downloads Developers Forum Support User guide Search syntax guide Contact us Contact us Helpdesk Feedback Twitter Blog Tech blog Developer Forum Europe PMC plus NOTICE: The ORCID Claiming tool has been temporarily disabled, because of technical issues. Please check back in later.", "truncated": false}
【tool:web_search】
{"ok": true, "query": "Europe PMC 22149876 BOLERO-2 abstract primary endpoint investigator review", "results": [{"title": "Everolimus in Postmenopausal Hormone-Receptor-Positive Advanced Breast ...", "url": "https://www.nejm.org/doi/full/10.1056/NEJMoa1109653", "snippet": "The primary end point was progression-free survival, on the basis of radiographic studies assessed by the local investigators , with central assessment by an independent radiology committee used in ..."}, {"title": "The BOLERO-2 trial: the addition of everolimus to ... - Europe PMC", "url": "https://europepmc.org/articles/PMC3466807", "snippet": "The BOLERO-2 trial met its primary end point of progression-free survival at the interim analysis. Results showed that the combination of everolimus with exemestane had increased efficacy compared with exemestane plus placebo with respect to progression-free survival in the range of 4-6 months in a patient population of postmenopausal ..."}, {"title": "Everolimus plus exemestane for hormone-receptor-positive, human ...", "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC6267855/", "snippet": "The primary end point was PFS as assessed by local investigator (per RECIST 1.0) [9]; OS was a key secondary end point. Safety assessments are described in the supplementary materials, available at Annals of Oncology online. Poststudy anticancer therapies were recorded for at least the first treatment after discontinuation."}, {"title": "Everolimus plus exemestane for hormone-r
【tool:web_search】
{"ok": true, "query": "\"PMID 22149876\" \"primary end point was PFS by local investigator review\"", "results": []}
→ call write_note({"tags":["fact","knowledge","4360dd15","clinical-trials","evidence-chain"],"text":"!! BO